Clinical Trial Update: Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports termination of a Phase 1/2 study evaluating PX-866 in combination with vemurafenib in patients with advanced melanoma harbori…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• PX-866 (PX-866)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Cascadian Therapeutics Inc. | Conditions: Advanced BRAF-mutant Cancers | Phase 1, Phase 2 | Status: TERMINATED